The Cuban Mambisa COVID-19 vaccine candidate concluded the period of clinical trials called “short cycle,” stipulated for days zero, 14 and 28 of the schedule, Prensa Latina reported. The drug, developed by scientists from the Cuban Center for Genetic Engineering and Biotechnology (CIGB), began human trials on December 7 with 88 volunteers, explained the head … Continue reading Cuban COVID-19 nasal vaccine concludes first phase of trials